Novartis applauds Ontario’s bold leadership in launching the FAST program, which accelerates access to breakthrough therapies like Scemblix ® for patients living with cancer. Scemblix ® (asciminib) ...
Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.
Below is a list of the treatments we currently offer via our Innovative Medicines Division. Visit Sandoz and Advanced Accelerator Applications to learn about our generics and radiopharmaceutical ...
Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker Scemblix data across clinical and real-world settings ...
ノバルティス ファーマ株式会社（本社：東京都港区、代表取締役社長：ジョンポール・プリシーノ）（以下「ノバルティス ファーマ」）は、日本の前立腺がんの治療経験に基づく視点を ...
Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each ...
Basel, November 20, 2025 – Novartis today rolled forward its mid-term guidance to 2025-2030 with a sales CAGR of +5-6% cc. The updated outlook will be featured at its Meet Novartis Management event in ...
ノバルティス ファーマ株式会社（本社：東京都港区、代表取締役社長：ジョンポール・プリシーノ、以下「ノバルティス ファーマ」）は、本日、眼科用血管内皮増殖因子（VEGF）阻害剤 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results